Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-09-26 02:15 CEST (UTC+2h)
 

syrup hybrid application [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2017-09-06 14:44  - Posting: # 17786
Views: 351

Hi Aga,

» How could we proof equivalence for syrups, to authorise strength 5 mg/ml when only lower strength of reference product is available (2 mg/ml)? BEQ? In vitro?
» The substance is present for more than half of a century on the market and efficacy for tablet (10 and 25 mg) and syrup lower strength (2 mg/ml) is documented in the literature.

Since you use the term "hybrid" I assume you imply EU submission? If so, get a scientific advice at three agencies. You might well see that they perceive such a case completely differently among the various agencies; some might allow this as a bibliographical application, some might want you to go 10.3 and others yet may think this is something else. If you run into someone fresh out of university this could easily get impractical especially if the syrup is not a solution.

I could be wrong, but…


Best regards,
ElMaestro

- since June 2017 having an affair with the bootstrap.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
17,323 Posts in 3,705 Threads, 1,068 registered users;
29 users online (0 registered, 29 guests).

It has yet to be proven
that intelligence has any survival value.    Arthur C. Clarke

The BIOEQUIVALENCE / BIOAVAILABILITY FORUM is hosted by
BEBAC Ing. Helmut Schütz
XHTML/CSS RSS Feed